

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT7245225

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	BIOPHARMAWORKS LLC	03/24/2022
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	LIXTE BIOTECHNOLOGY, INC.	
<b>Street Address:</b>	680 EAST COLORADO BLVD., SUITE 180	
<b>City:</b>	PASADENA	
<b>State/Country:</b>	CALIFORNIA	
<b>Postal Code:</b>	91101	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	Application Number:	17586548
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(202)842-7899	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Email:</b>	sdivenere@cooley.com, z/IPPatentdocketingmailboxus@cooley.com	
<b>Correspondent Name:</b>	COOLEY LLP	
<b>Address Line 1:</b>	1299 PENNSYLVANIA AVENUE NW, SUITE 700	
<b>Address Line 4:</b>	DC, WASHINGTON 20004	
<b>ATTORNEY DOCKET NUMBER:</b>	LXTE-020/05US 345620-2355	
<b>NAME OF SUBMITTER:</b>	MATTHEW E. LANGER	
<b>SIGNATURE:</b>	/Matthew E. Langer/	
<b>DATE SIGNED:</b>	03/25/2022	
<b>Total Attachments: 6</b>		
source=LXTE-020_05US Biopharma to Lixte#page1.tif		
source=LXTE-020_05US Biopharma to Lixte#page2.tif		
source=LXTE-020_05US Biopharma to Lixte#page3.tif		
source=LXTE-020_05US Biopharma to Lixte#page4.tif		
source=LXTE-020_05US Biopharma to Lixte#page5.tif		
source=LXTE-020_05US Biopharma to Lixte#page6.tif		

**ASSIGNMENT OF PATENT RIGHTS**  
**(Company to Company)**

**BIOPHARMAWORKS LLC**, having its principal place of business at 93 Shennecossett Road, Groton, CT 06340 (herein referred to as "Assignor") owns an undivided interest in the entire right, title and interest in the Patent application(s) ("said application(s)") set forth below, as well as any invention(s) ("said invention(s)") disclosed in said application(s).

Patent Application(s)

Application No.: 17/586,548

Filing Date: January 27, 2022

Title: OXABICYCLOHEPTANE PRODRUGS

wherein the above application(s) claim(s) priority from and the benefit of:

Country	Application No.	Application filing date
US	16/782,970	February 5, 2020
US	16/439,227	June 12, 2019
US	15/968,462	May 1, 2018
US	15/154,304	May 13, 2016
US	62/162,501	May 15, 2015

**WHEREAS, LIXTE BIOTECHNOLOGY, INC.**, having its principal place of business at 680 East Colorado Blvd., Suite 180, Pasadena, CA 91101 (the "Assignee"), its successors, legal representatives and assigns, is desirous of acquiring the Assignor's entire right, title, and interest in and to said invention(s), said application(s), and said patent(s); the right to file applications for patent and/or registered design of the United States or other countries on said invention(s); the entire right, title and interest in and to any application(s) and patent(s); the right to recover any and all past, present, and future damages, including provisional or other royalties, for any and all past, present, and future infringements of said application(s) for patent and/or registered design and said patent(s); and the entire right, title, and interest in and to any and all Letters Patent or Patents and/or registered design(s), United States or foreign, to be obtained for said invention(s) and said application(s);

**NOW, THEREFORE**, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee or a predecessor in interest of the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee or a predecessor in interest of the Assignee then in confirmation of said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns Assignor's right, title, and interest in and to:

- (a) said invention(s);
- (b) said application(s) for patent;
- (c) said patent(s);
- (d) the right to file applications for patent and/or registered design of the United States or other countries on said invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, and all rights of claiming priority in any country of the world;
- (e) any application(s) for patent and/or registered design of the United States or other countries claiming the invention(s);
- (f) any application(s) for patent and/or registered design of the United States or other countries claiming priority to, and/or the benefit of, at least one of the application(s) for patent and/or registered design identified above or any application(s) for patent claiming the invention(s), including any priority application(s), substitute application(s), division(s), continuation(s), and continuation(s)-in-part;
- (g) the right to recover any and all past, present, and future damages, including provisional or other royalties, for any and all past, present, and future infringements of said application(s) for patent and/or registered design and said patent(s) identified in the preceding paragraphs (b)-(f) and of any and all patent(s) and/or registered design(s) granted based thereon in the United States and in all other countries; and
- (h) any and all Letters Patent or Patents and/or registered design(s), United States or foreign, to be obtained for said invention(s), said application(s), and said patent(s), including any reissue(s), reexamination(s), revival(s), renewal(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made;

**AND** for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is the sole and lawful owner of Assignor's entire right, title and interest in and to said invention(s), said application(s), and said patent(s), and that the same are unencumbered, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth;

**AND** for the same consideration, the Assignor also hereby represents that, except for said prior agreement, if applicable, the Assignor has not previously sold, transferred, or encumbered any part of Assignor's right, title, and interest in the Invention(s);

**AND** for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns that the Assignor will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with said invention(s), said application(s), said registered design(s), said patent(s), any application claiming priority to said application(s), any reissue or extension of said patent(s), and any United States or foreign Letters Patent or Patents for said invention(s) or said application(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.), is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said invention(s), without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns;

**AND** the Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided the application number, filing date and attorney docket number, of the Patent Application(s) identified herein when known;

**AND** the Assignor hereby requests the Commissioner of Patents to issue any and all aforementioned patent(s) of the United States to the Assignee, as the Assignee of said invention(s) and the Letters Patent to be issued thereon for the use and behalf of the Assignee, its successors, legal representatives, and assigns;

**AND** Assignor(s) and Assignee(s) understand that electronic signatures are acceptable and that, by signing electronically, signatories agree to the use of electronic signatures.

Date: MARCH 24, 2022 By: Robert A. Volkman  
Name: ROBERT A. VOLKMAN  
Title: CSO  
Company: BIOPHARMAWORKS LLC

By signing, I confirm that I am entitled to sign legally binding acts on behalf of  
**BIOPHARMAWORKS LLC.**

Witness:

Frederick R. Nelson  
Signature

03/24/2022  
Date

Frederick R. Nelson  
Printed name

Witness:

Panayiotis Zagouras  
Signature

03/24/2022  
Date

Panayiotis Zagouras  
Printed name

For and on behalf of ASSIGNEE:

Date: 24 MARCH 2022

By: 

Name: John S. Kovach

Title: CEO and Founder

Company: Lixte Biotechnology, Inc.

Witness:

Rabun C. Kovach

Signature

24 March 2022

Date

BARBARA C. V. KOVACH

Printed name

Witness:

Signature

Date

Printed name

0517961273 v1